Test your novel Parkinson’s disease therapeutics aimed at targeting intracellular lysosomal pathways in the LRRK2 model
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene, which encodes a kinase with a multitude of cellular functions (e.g., lysosomal function), are associated with PD. In line, the inhibition of LRRK2 is being increasingly pursued as a therapeutic strategy in PD treatment.
Take advantage of InnoSer’s expertise in modelling PD pathology, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience with modelling LRRK2 pathology in vivo and are happy to help guide your decision on a study design fit for your current research goals.
LRRK2 model key model characteristics:
- Transgenic mouse model with human LRRK2 with disease associated mutations (e.g., G2019S).
- Combination of LRRK2 models with alpha-synuclein models (e.g., seeding).
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Test the efficacy of your treatments with the following biological readouts:
- MSD (e.g. LRRK2 levels)
- Immunofluorescence and FISH
Related Parkinson’s Disease model options
MPTP Induced PD Models
Transgenic Alpha-Synuclein Models
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know